Learn the Latest In CAR T with ASTCT Webinars

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.

Cristiane Decat Bergerot, PhD

April 14th 2025

FDA Clears IND for VS-7375 in KRAS 612D-Mutated Advanced Solid Tumors

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-612D mutation.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Funding is the Greatest Need in Neuroendocrine Tumor Research

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Ariana Pelosci

Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma

An annual report on the status of cancer showed that, from 2018 to 2022, the cancer death rate fell for every race and ethnicity.

Related Content

American Society for Transplantation and Cellular Therapy

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.

Cristiane Decat Bergerot, PhD

April 14th 2025

FDA Clears IND for VS-7375 in KRAS 612D-Mutated Advanced Solid Tumors

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a KRAS-612D mutation.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Funding is the Greatest Need in Neuroendocrine Tumor Research

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Ariana Pelosci

Cancer Mortality Shows Long-Term Declines Despite COVID-19 Pandemic

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.